AbCellera Biologics (ABCL) Deferred Taxes (2021)

AbCellera Biologics (ABCL) posted Deferred Taxes of $1.2 million for Q4 2021, up 131.05% on a QoQ basis from -$4.0 million in Q3 2021.

AbCellera Biologics (ABCL) Deferred Taxes (2021) Analysis & Trends

AbCellera Biologics' Deferred Taxes history runs 1 years deep, the most recent figure standing at $1.2 million for Q4 2021.

Quarterly Deferred Taxes changed N/A year-over-year to $1.2 million in Q4 2021, while the trailing twelve-month figure through Dec 2021 was -$2.0 million (changed N/A YoY) and the FY2023 annual result came in at $2.0 million, up 192.72% from the prior year.
Deferred Taxes was $1.2 million for Q4 2021 at AbCellera Biologics, up from -$4.0 million in the prior quarter.
Across five years, Deferred Taxes topped out at $1.2 million in Q4 2021 and bottomed at -$4.0 million in Q3 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Deferred Taxes (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-188,883.60
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-65.30 Mn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	96.00 Mn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	AbCellera Biologics	1.72 Bn	1.72 Bn	-	-

Download Data